Silver Named to TScan Therapeutics Board of Directors
7 January 2021 - - US-based biopharmaceutical company TScan Therapeutics has appointed Brian M. Silver, J.D., to its board of directors, the company said.

Silver is chief financial officer and head of corporate development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.

Prior to joining Freeline in 2018, Silver was partner and head of biotechnology in the healthcare practice at Perella Weinberg Partners, an independent global advisory firm.

Prior to Perella Weinberg, Silver held a number of positions in Morgan Stanley's healthcare investment banking group, most recently as Managing director from 1998 to 2013.

He began his career in the corporate transactions group at Sullivan and Cromwell. His advisory experience spans dozens of transactions, including mergers and acquisitions, joint ventures and licenses, and capital raises across the equity, debt, convertible and royalty finance markets.

TScan discovers and develops T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases.